tbuckley/cabot-search huggingface dataset:
Colon‐Targeted Ginseng Polysaccharides‐Based Microspheres for Improving Ulcerative Colitis via Anti‐Inflammation and Gut Microbiota Modulation
Authors: De‐yang Huo, Yan‐fei Li, Ling‐jie Song, Wen‐xin Zhang, Xin‐dian Li, Jing Zhang, Shen Ren, Zi Wang, Wei Li
Journal: Advanced Healthcare Materials (2025)

Abstract Natural plant‐derived polysaccharides exhibit substantial potential for treating ulcerative colitis (UC) owing to their anti‐inflammatory and antioxidant properties and favorable safety profiles. However, their practical application faces several challenges, including structural instability in gastric acid, imprecise targeting of inflamed regions, and limited intestinal retention times. To address these limitations, pH‐responsive, colon‐targeting microspheres (pWGPAC MSs) are developed for delivering phosphorylated wild ginseng polysaccharides (pWGP) to alleviate UC. These pWGPAC MSs are fabricated by incorporating pWGP into calcium‐crosslinked alginate microspheres with subsequent chitosan surface modification to enhance mucosal adhesion. These pWGPAC MSs demonstrated exceptional stability under acidic conditions while enabling targeted release in the colon. In a mouse model of UC, the pWGPAC MSs effectively mitigated mucosal injury, attenuated inflammation, and restored intestinal barrier function. Further mechanistic investigations revealed that these pWGPAC MSs modulated the TLR4/MYD88 signaling pathway and promoted M2 macrophage polarization. Integrated microbiome and metabolome analyses demonstrated that these pWGPAC MSs regulated the gut microbiota composition and decreased pro‐inflammatory metabolite levels. In addition, these microspheres demonstrated promising safety profiles. Collectively, these findings establish pWGPAC MSs as a promising therapeutic strategy for the treatment of UC and provide a solid foundation for future clinical applications.
Mir-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via chromatin loops to promote the malignant progression of hepatocellular carcinoma
Authors: Weiwei Chen, Chutian Wu, Yuting Li, Tonghua Wang, Miaoling Huang, Min Wang, Linjing Long, Yanfang Chen, Shufen Feng, Xuyou Liu, Shaohui Tang
Journal: Molecular Cancer (2025)

The insulin-like growth factor 2 (IGF2) and H19 are overexpressed in hepatocellular carcinoma (HCC). IGF2-derived miR-483-5p is implicated in the development of cancers. Here, we investigated the involvement of miR-483-5p in IGF2 and H19 overexpression regulation and its role in HCC. Firstly, the effect of miR-483-5p on the expression of IGF2 and H19, and the binding of miR-483-5p to IGF2/H19 enhancer were evaluated in HCC cells. Next, miR-483-5p-mediated IGF2/H19 enhancer activation and its mechanism were investigated in HCC cells. Then, the mechanism by which active IGF2/H19 enhancer mediated by miR-483-5p activate IGF2/H19 promoters was studied in HCC cells. Finally, the effect of MED1 on the expression of IGF2/H19 as well as the malignant phenotype of HCC cells in vitro and in vivo mediated by miR-483-5p was evaluated. Mir-483-5p up-regulated IGF2 P2 mRNA-P4 mRNA and H19 expression by binding to IGF2/H19 enhancer resulting in IGF2/H19 enhancer activation in HCC cells. Mechanistically, miR-483-5p increased recruitment of Ago1 and Ago2 at IGF2/H19 enhancer and then activated transcription of IGF2/H19 eRNA by RNA polymerase II and p300, which further induced chromatin loops formation between IGF2/H19 enhancer and IGF2/H19 promoters to activate IGF2/H19 promoters via IGF2/H19 eRNA-MED1-IGF2/H19 promoters complex in HCC cells. In this process, MED1 promoted chromatin loops formation as well as the malignant phenotype of HCC cells in vitro and in vivo mediated by miR-483-5p. miR-483-5p-mediated activating of IGF2/H19 enhancer up-regulates IGF2/H19 expression via DNA loops, thereby promoting the malignant progression of HCC.
Electroactive Asymmetric Dressing for Spatiotemporal Deep Burn Scarless Healing and Management
Authors: Hanbai Wu, Xiong Zhou, Chuanwei Zhi, Cong Wang, Yuhan Chen, Yifan Si, Jieqiong Yang, Qi Zhang, Raymond H. W. Lam, Tingwu Qin, Guibing Fu, Zhu Xiong, Jinlian Hu
Journal: Advanced Healthcare Materials (2025)

Burn care and treatment differ markedly from other types of wounds, as they are significantly more prone to infections and struggle to maintain fluid balance post-burn. Moreover, the limited self-healing abilities exacerbate the likelihood of scar formation, further complicating the recovery process. To tackle these issues, an asymmetric wound dressing comprising a quercetin-loaded poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (P34HB@Qu) hydrophilic layer and a zinc oxide nanoparticle-loaded, thermally treated polyvinylidene fluoride (HPVDF@ZnO) hydrophobic layer is designed. This dressing provided antibacterial property and exudate management in the early stages of burn treatment, preventing infection and maintaining moisture balance at the wound site. As healing progresses, the electroactive properties of HPVDF@ZnO and quercetin from P34HB@Qu synergistically regulate cell migration and differentiation, accelerating wound healing and facilitating scar-free regeneration. Furthermore, the wound dressing assisted in the regeneration of skin appendages. This study underscores the full-cycle strategy of versatile wound dressings for spatiotemporal burn wound management from injury to scarless healing.
Bathing with 2% chlorhexidine gluconate versus routine care for preventing surgical site infections after pancreatic surgery: a single centre randomised controlled trial
Authors: Wen-Sen Chen, Jian-Zhen Lin, Kai Zhang, Xiao-Ping Fang, Rong Wang, Qing-Mei Sun, Hui-Ping Yu, Xu Feng, Zhan-Jie Li, Yue Yang, Qing-Tang Zhu, Feng Zang, Kui-Rong Jiang, Gui-Hua Zhuang
Journal: Clinical Microbiology and Infection (2025)
Shared social identity and social safety as health promoting factors for gender diverse individuals with a chronic illness and/or disability: A qualitative analysis of intersectional experiences
Authors: Hallie Decker, Ryan Combs, Alex Cowand, Emily Noonan, Laura Weingartner, Lesley Harris, Sara Williams
Journal: International Journal of Transgender Health (2025)

Background Gender diverse people with a chronic illness and/or disability (CI/D) encounter stigma and disempowerment at all social-ecological levels, reducing access to individual health promoting behaviors and resulting in population health disparities. Living at the intersection of two populations experiencing social marginalization, this group is also at higher risk of experiencing chronic stress—a factor that leads to suboptimal health outcomes over the life span.
Anisotropic structure of nanofiber hydrogel accelerates diabetic wound healing via triadic synergy of immune-angiogenic-neurogenic microenvironments
Authors: Kunkoo Kim, Jia Yang, Chengli Li, Chun-Yi Yang, Peilun Hu, Yaosai Liu, Yin-Yuan Huang, Xiaohan Sun, Ming Chi, Chenyu Huang, Xiaodan Sun, Lingyun Zhao, Xiumei Wang
Journal: Bioactive Materials (2025)
Early Puberty and Risk of Asthma: Meta‐Analysis and Systematic Review
Authors: Fu‐Min Chang, Yung‐Feng Lin, Hsiao‐Chi Chuang, Jhih‐Wei Hsu, Yang‐Ching Chen
Journal: Allergy (2025)

Data sharing is not applicable to this article as no new data were created or analyzed in this study. Appendix S1 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Investigating the delivery of PD-L1-targeted immunoliposomes in a dynamic cervical cancer-on-a-chip model
Authors: Seth-Frerich Fobian, Mohamadreza Amin, Andrea Sacchetti, Arlene L Oei, Timo L M Ten Hagen
Journal: Journal of Controlled Release (2025)

The recent approval of pembrolizumab in recurrent or metastatic cervical cancer warrants further investigations into the usefulness of immunotherapies for more durable and less radical interventions. In this study, the targeting potential of anti-PD-L1-functionalized immunoliposomes was tested in a 3D in vitro cervical cancer-on-a-chip model. Immunolipsomes were synthesized and decorated externally with monovalent anti-PD-L1 Fab' fragments of commercially available atezolizumab. Cervical cancer cell lines with varying levels of PD-L1 expression were cultured as spheroids embedded in a collagen I matrix, and treated under flow of culture media. Flow cytometry and live-cell confocal imaging were used to measure the interactions and uptake of untargeted liposomes and immunoliposomes in this panel of cell lines. The immunoliposomes retained specific functionality regardless of protein corona formation in high serum environments. As such, spheroids expressing high levels of PD-L1 preferentially internalized immunoliposomes in a 3D environment with extracellular matrix present, while low PD-L1-expressing cell lines showed no preference for either formulation. Importantly, treatments performed in monolayer cultures (on plastic) showed no differences between immuno- and untargeted liposome uptake, including the way in which the endocytosed liposomes are trafficked subcellularly. This study demonstrates the importance of both active and passive accumulation strategies to achieve nanoparticle targeting. Immunoliposomes remain a promising platform for the development of targeted nanotherapies against cervical cancers. However, initial functional tests did not translate directly to biological performance and this should be kept in mind for future formulations. Furthermore, the in vitro model developed appeared useful for visualizing liposome uptake in a 3D, live tissue environment and represents a cost-effective and reproducible model for future studies.
Identification of cardiac wall motion abnormalities in diverse populations by deep learning of the electrocardiogram
Authors: Albert J. Rogers, Neal K. Bhatia, Sabyasachi Bandyopadhyay, James Tooley, Rayan Ansari, Vyom Thakkar, Justin Xu, Jessica Torres Soto, Jagteshwar S. Tung, Mahmood I. Alhusseini, Paul Clopton, Reza Sameni, Gari D. Clifford, J. Weston Hughes, Euan A. Ashley, Marco V. Perez, Matei Zaharia, Sanjiv M. Narayan
Journal: npj Digital Medicine (2025)

Cardiac wall motion abnormalities (WMA) are strong predictors of mortality, but current screening methods using Q waves from electrocardiograms (ECGs) have limited accuracy and vary across racial and ethnic groups. This study aimed to identify novel ECG features using deep learning to enhance WMA detection, referencing echocardiography as the gold standard. We collected ECG and echocardiogram data from 35,210 patients in California and labeled WMA using unstructured language parsing of echocardiographic reports. A deep neural network (ECG-WMA-Net) was trained and outperformed both expert ECG interpretation and Q-wave indices, achieving an AUROC of 0.781 (CI: 0.762–0.799). The model was externally validated in a diverse cohort from Georgia (n = 2338), with an AUC of 0.723 (CI: 0.685–0.757). Explainability analysis revealed significant contributions from QRS and T-wave regions. This deep learning approach improves WMA screening accuracy, potentially addressing physiological differences not captured by standard ECG-based methods.
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Authors: Guadalupe Oñate, Ana Garrido, Montserrat Arnan, Helena Pomares, Ester Alonso, Mar Tormo, Marina Diaz-Beya, Susana Vives, Lurdes Zamora, Antonia Sampol, Rosa Coll, Olga Salamero, Marta Cervera, Antoni Garcia, Ferran Vall-Llovera, Sara Garcia-Avila, Joan Bargay, Xavier Ortin, Eva Iranzo, Francisca Guijarro, Marta Pratcorona, Josep F. Nomdedeu, Jordi Esteve, Jorge Sierra
Journal: Blood Cancer Journal (2025)

Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will perform poorly, and in whom alternative approaches deserve investigation. We analyzed 1034 fit adults ≤70 years intensively treated between 2012 and 2022 in the CETLAM group. Young adults ( ≤ 60 years) presented higher remission rates and improved survival than older adults above that age (CR 79% vs. 73%; p = 0.03 and 4-yr OS 53% vs. 33%; p < 0.001). Remission and survival outcomes varied among different genetic subsets. An especially adverse genetic group included complex, monosomal karyotype, TP53 alterations (deleted/mutated), and MECOMr. Transplant feasibility in this very adverse risk group was low, and OS and EFS at 4 years were 14% and 12%, in contrast to 70% and 57% in the favorable group and 38% and 32% in all other patients. We integrated clinical and genetic data into the Intensive Chemotherapy Score for AML (ICSA) with 6-risk categories with significantly different remission rates and OS, validated in another cohort of 581 AML patients from a previous CETLAM protocol. In summary, we identified groups of fit patients that benefit differently from an intensive approach which may be helpful in future treatment decisions.
Ramadan intermittent fasting for patients with gastrointestinal and hepatobiliary diseases: practical guidance for health-care professionals
Authors: Muhammad Usman, Nasir Javed, Aida Jawhari, Nazim Ghouri, Salman Waqar, Fathima Shah, Saqib Ahmad, Ailsa Hart, Bilal Hameed, Mohammad Qasim Khan, Mohammad Farhad Peerally
Journal: The Lancet. Gastroenterology & hepatology (2025)
Whole examination AI estimation of fetal biometrics from 20-week ultrasound scans
Authors: Lorenzo Venturini, Samuel Budd, Alfonso Farruggia, Robert Wright, Jacqueline Matthew, Thomas G. Day, Bernhard Kainz, Reza Razavi, Jo V. Hajnal
Journal: npj Digital Medicine (2025)

Abstract The current approach to fetal anomaly screening is based on biometric measurements derived from individually selected ultrasound images. In this paper, we introduce a paradigm shift that attains human-level performance in biometric measurement by aggregating automatically extracted biometrics from every frame across an entire scan, with no need for operator intervention. We use a neural network to classify each frame of an ultrasound video recording. We then measure fetal biometrics in every frame where appropriate anatomy is visible. We use a Bayesian method to estimate the true value of each biometric from a large number of measurements and probabilistically reject outliers. We performed a retrospective experiment on 1457 recordings (comprising 48 million frames) of 20-week ultrasound scans, estimated fetal biometrics in those scans and compared our estimates to real-time manual measurements. Our method achieves human-level performance in estimating fetal biometrics and estimates well-calibrated credible intervals for the true biometric value.
Medication reviews in hospitalised patients for reduced hospital readmission and mortality. Systematic review, meta-analysis and meta-regression of RCTs
Authors: Miriam Degen, Li-Ju Chen, Ben Schöttker
Journal: Ageing Research Reviews (2025)

Efforts to reduce preventable medication-related harm through medication reviews have increased, but interventions often yield null-results regarding clinical outcomes. We conducted a systematic literature search in four data bases and summarised the available evidence from randomised controlled trials (RCTs) comparing medication reviews and usual care in hospitalised patients regarding hospital readmissions and all-cause mortality by random-effects meta-analyses. Effect size differences by methodological study differences were of special interest. The meta-analysis of all 24 trials on hospital readmissions, including 12,539 participants, showed a statistically significant 8% decrease in hospital readmissions (risk ratio (RR) [95% confidence interval]: (0.92 [0.88-0.97], p=0.002). The number of patient contacts was the most prominent effect modifier in meta-regression (p=0.003) and the effect of medication reviews was approximately twice as strong (15%) in 11 trials with 2 or more patient contacts (0.85 [0.78-0.92], p<0.001). No statistically significant reduction in all-cause mortality was observed in a meta-analysis of all 22 trials with data for this outcome (0.95 [0.86-1.04], p=0.24), including 12,350 participants. The method of mortality assessment was identified as an effect modifier by meta-regression (p=0.01). A meta-analysis of 10 trials with complete mortality ascertainment via registries or primary care data showed a significantly 19% reduced mortality (0.81 [0.70-0.94], p<0.01)). In conclusion, medication reviews reduce the risk of hospital readmission and might also reduce all-cause mortality. Comprehensive mortality assessment was essential for successful trials. Clinical guidelines should recommend medication reviews with multiple patient contacts, involving pharmacists, either for repeated medication reviews or to improve adherence.
Disease stage-specific role of the mitochondrial pyruvate carrier suppresses differentiation in temozolomide and radiation-treated glioblastoma
Authors: Emma Martell, Helgi Kuzmychova, Harshal Senthil, Ujala Chawla, Esha Kaul, Akaljot Grewal, Versha Banerji, Christopher M Anderson, Chitra Venugopal, Donald Miller, Tamra E Werbowetski-Ogilvie, Sheila K Singh, Tanveer Sharif
Journal: Neuro-Oncology (2025)

Abstract Background The mitochondrial pyruvate carrier (MPC), a central metabolic conduit linking glycolysis and mitochondrial metabolism, is instrumental in energy production. However, the role of the MPC in cancer is controversial. In particular, the importance of the MPC in glioblastoma (GBM) disease progression following standard temozolomide (TMZ) and radiation therapy (RT) remains unexplored. Methods Leveraging in vitro and in vivo patient-derived models of TMZ-RT treatment in GBM, we characterize the temporal dynamics of MPC abundance and downstream metabolic consequences using state-of-the-art molecular, metabolic, and functional assays. Results Our findings unveil a disease stage-specific role for the MPC, where in post-treatment GBM, but not therapy-naïve tumors, the MPC acts as a central metabolic regulator that suppresses differentiation. Temporal profiling reveals a dynamic metabolic rewiring where a steady increase in MPC abundance favors a shift towards enhanced mitochondrial metabolic activity across patient GBM samples. Intriguingly, while overall mitochondrial metabolism is increased, acetyl-CoA production is reduced in post-treatment GBM cells, hindering histone acetylation and silencing neural differentiation genes in an MPC-dependent manner. Finally, the therapeutic translations of these findings are highlighted by the successful pre-clinical patient-derived orthotopic xenograft (PDOX) trials utilizing a blood-brain-barrier (BBB) permeable MPC inhibitor, MSDC-0160, which augments standard TMZ-RT therapy to mitigate disease relapse and prolong animal survival. Conclusion Our findings demonstrate the critical role of the MPC in mediating GBM aggressiveness and molecular evolution following standard TMZ-RT treatment, illuminating a therapeutically-relevant metabolic vulnerability to potentially improve survival outcomes for GBM patients.
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population
Authors: J F Seligmann, D Morton, F Elliott, K Handley, R Gray, M Seymour, B Glimelius, L Magill, C J M Williams, P Quirke, D Bottomley, H M Wood, K Murakami, A D Beggs, N P West
Journal: Annals of Oncology (2025)
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein–overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib
Authors: H Horinouchi, B C Cho, D R Camidge, K Goto, P Tomasini, Y Li, A Vasilopoulos, P Brunsdon, D Hoffman, W Shi, E Bolotin, V Blot, J Goldman
Journal: Annals of Oncology (2025)
Structural determinants of peanut induced anaphylaxis
Authors: Scott A Smith, Rebecca A Shrem, Bruno B C Lança, Jian Zhang, Joyce J W Wong, Derek Croote, R Stokes Peebles, Benjamin W Spiller
Journal: Journal of Allergy and Clinical Immunology (2025)

Human monoclonal IgE antibodies recognizing peanut allergens have recently become available, but we lack a detailed understanding of how these IgEs target allergens. To determine the molecular details of the antibody-allergen interaction for a panel of clinically important human IgE monoclonal antibodies and to develop strategies to disrupt disease causing antibody-allergen interactions. We identified candidates from a panel of epitope binned human IgE monoclonals that recognize two important and homologous peanut allergens, Ara h 2 and Ara h 6. Crystal structures were determined revealing the interfaces (antigenic sites) of exemplars of five common IgE bins. Among the common antigenic sites on Ara h 2 and Ara h 6, two sites (A and B) are highly conserved between the allergens, explaining the cross reactivity of antibodies that recognize these sites. Three sites (C, D, and F) involve residues that are not conserved between the allergens. Of the five common sites, three Sites (B, C, and D) involve residues that are only near each other when the allergens are properly folded, such that these sites are conformational. Two additional sites (sites A and F) involve largely linear stretches of amino acids. Site F targeted antibody, 38B7, binds to a peptide sequence DPYSPOHS, in which hydroxylation of the last proline is critical for binding. This sequence is repeated two or three times depending on the Ara h 2 isoform, enabling 38B7 to induce anaphylaxis as a single monoclonal, without a second antibody. We have mutated key residues in each site and created a panel of hypoallergens, having reduced IgE mAb binding and lacking the ability to induce anaphylaxis in our murine model. We created a structural map of the IgE antibody response to the most important peanut allergen proteins to enable the design of new allergy immunotherapies and vaccines.
DOC2b enrichment mitigates proinflammatory cytokine-induced CXCL10 expression by attenuating IKKβ and STAT-1 signaling in human islets
Authors: Diti Chatterjee Bhowmick, Miwon Ahn, Supriyo Bhattacharya, Arianne Aslamy, Debbie C Thurmond
Journal: Metabolism (2025)